In conclusion, assays targeting heterogeneity in HDL's main apolipoprotein, apoA-I, could provide a potential approach to improving the identification of patients with a risk of developing coronary atherosclerosis. This evidence concerns the gene APOA1 and coronary atherosclerosis.